FULGENT GENETICS, INC. Restricted Cash and Cash Equivalents
FULGENT GENETICS, INC. (FLGT) had Restricted Cash and Cash Equivalents of $135.00 thousand as of 2025-09-30, per its 10-Q filed 2025-11-07.
Financial Statements › Balance Sheet › Assets › Restricted Cash and Cash Equivalent
us-gaap:RestrictedCashAndCashEquivalents · last filed 2025-11-07
- 2025-09-30: Restricted Cash and Cash Equivalents $135.00K.
- 2025-06-30: Restricted Cash and Cash Equivalents $135.00K.
- 2025-03-31: Restricted Cash and Cash Equivalents $135.00K.
- 2024-12-31: Restricted Cash and Cash Equivalents $135.00K.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2025-09-30 | $135.00K 10-Q · filed 2025-11-07 |
| 2025-06-30 | $135.00K 10-Q · filed 2025-08-01 |
| 2025-03-31 | $135.00K 10-Q · filed 2025-05-02 |
| 2024-12-31 | $135.00K 10-K · filed 2025-02-28 |
| 2024-09-30 | $135.00K 10-Q · filed 2025-11-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |